-
1دورية أكاديمية
المؤلفون: Koichi Saruwatari, Ryo Sato, Shunya Nakane, Shinya Sakata, Koutaro Takamatsu, Takayuki Jodai, Remi Mito, Yuko Horio, Sho Saeki, Yusuke Tomita, Takuro Sakagami
المصدر: Cancers, Vol 11, Iss 2, p 140 (2019)
مصطلحات موضوعية: anti-PD-1 monoclonal antibodies, anti-acetylcholine receptor (AChR) antibody, B cell, immune checkpoint blockade, immune-related adverse events (irAEs), myasthenia gravis (MG), non-small-cell lung cancer (NSCLC), nivolumab, programmed cell death ligand 1 (PD-L1), T cell, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
2
المؤلفون: Shinya Sakata, Ryo Sato, Shunya Nakane, Koichi Saruwatari, Koutaro Takamatsu, Remi Mito, Takuro Sakagami, Yuko Horio, Sho Saeki, Takayuki Jodai, Yusuke Tomita
المصدر: Cancers
Cancers, Vol 11, Iss 2, p 140 (2019)مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.drug_class, non-small-cell lung cancer (NSCLC), non-small cell lung cancer (NSCLC), Monoclonal antibody, lcsh:RC254-282, anti-acetylcholine receptor (AChR) antibody, 03 medical and health sciences, anti-PD-1 monoclonal antibodies, 0302 clinical medicine, Immune system, medicine, Lung cancer, myasthenia gravis (MG), nivolumab, B cell, immune-related adverse events (irAEs), biology, business.industry, Communication, T cell, Cancer, immune checkpoint blockade, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Immune checkpoint, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Immunology, programmed cell death ligand 1 (PD-L1), biology.protein, Antibody, Nivolumab, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d4a722e56fcba605a0f85a1b1d92c8Test
https://doi.org/10.3390/cancers11020140Test